May 19, 2022

Volume XII, Number 139

Advertisement
Advertisement

May 18, 2022

Subscribe to Latest Legal News and Analysis

May 17, 2022

Subscribe to Latest Legal News and Analysis

May 16, 2022

Subscribe to Latest Legal News and Analysis
Advertisement

340B Update: HRSA Moves Forward with 340B ADR Rule as Covered Entities Challenge Contract Pharmacy Actions [PODCAST]

In this episode of Triage, Andrew Ruskin and Victoria Hamscho provide an update on recent developments in the 340B Program and, in particular, on two recent legal challenges covered entities brought in response to drug manufacturer contract pharmacy actions where they are requesting, among other things, for the Health Resources and Services Administration (HRSA) to promulgate 340B administrative dispute resolution regulations, which HRSA recently sent to the Office of Management and Budget for review.

 

Copyright 2022 K & L GatesNational Law Review, Volume X, Number 338
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Andrew D. Ruskin Health Care Attorney K&L Gates Washington, D.C.
Partner

Andrew Ruskin is a partner in the firm’s Washington, D.C. office. He is a member of the health care and FDA practice group.

Areas of Focus 

  • Health Care and FDA
  • Food, Drugs, Medical Devices, and Cosmetics (FDA)
202-778-9415
Victoria K. Hamscho Public Policy & Law Attorney K&L Gates Washington, D.C.
Associate

Victoria Hamscho is an associate in the firm’s Washington, D.C. office, where she is a member of the public policy and law practice group. Ms. Hamscho focuses her practice on legislative and regulatory matters impacting health care industry clients and large employers, including the Affordable Care Act implementation, Medicare and Medicaid reimbursement, and 340B Drug Pricing Program enrollment and compliance. Ms. Hamscho works on legislative matters before the House Ways and Means Committee, House Energy and Commerce Committee, Senate Finance Committee, and Senate Health Education Labor...

202-778-9137
Advertisement
Advertisement
Advertisement